Uncategorized

PDF Applications of Antisense Therapies to Restenosis

Free download. Book file PDF easily for everyone and every device. You can download and read online Applications of Antisense Therapies to Restenosis file PDF Book only if you are registered here. And also you can download or read online all Book PDF file that related with Applications of Antisense Therapies to Restenosis book. Happy reading Applications of Antisense Therapies to Restenosis Bookeveryone. Download file Free Book PDF Applications of Antisense Therapies to Restenosis at Complete PDF Library. This Book have some digital formats such us :paperbook, ebook, kindle, epub, fb2 and another formats. Here is The CompletePDF Book Library. It's free to register here to get Book file PDF Applications of Antisense Therapies to Restenosis Pocket Guide.

Update Location. If you want NextDay, we can save the other items for later.

Table of contents

Yes—Save my other items for later. No—I want to keep shopping. Order by , and we can deliver your NextDay items by. In your cart, save the other item s for later in order to get NextDay delivery.


  • The Four Seasons: A Novel of Vivaldis Venice.
  • Monetary History of Mughal India as Reflected in Silver Coin Hoards.
  • War in France and Belgium in 1815.
  • Kundrecensioner.

We moved your item s to Saved for Later. There was a problem with saving your item s for later.

Novel PDGFβR antisense encapsulated in polymeric nanospheres for the treatment of restenosis

You can go to cart and save for later there. Applications of Antisense Therapies to Restenosis. Average rating: 0 out of 5 stars, based on 0 reviews Write a review. LeRoy E Rabbani. Tell us if something is incorrect.

Applications of Antisense Therapies to Restenosis - Semantic Scholar

Add to Cart. Free delivery. Arrives by Thursday, Oct 3. Or get it by Wed, Sep 25 with faster delivery. Pickup not available.

by Springer

About This Item We aim to show you accurate product information. Manufacturers, suppliers and others provide what you see here, and we have not verified it. In addition to assuming all program costs, Cook has entered into a supply agreement to purchase the drugs for development, clinical studies and commercialization from AVI.


  • Advances in the Forensic Analysis and Dating of Writing Ink;
  • Collecting food and drink books!
  • Classification and diagnosis of psychological abnormality.
  • Leibniz: Nature and Freedom.
  • Applications of Antisense Therapies to Restenosis | SpringerLink?

Thus far there have not been any safety issues with the administration of antisense or the bubble formulation. Our early findings are very encouraging. Resten-NG AVI is a third-generation antisense agent that targets the key regulatory gene involved in cardiovascular restenosis, the transcription factor referred to as c-myc.

Customer Reviews

It is believed to regulate the many downstream genes that produce the pathology of restenosis, namely cell migration and adhesion, collagen formation, secretion of extra-cellular matrix, and cell proliferation, among others. The c-myc gene expression is immediately activated by the injury to the vascular lining during angioplasty and stent placement, and peaks at 24 hours to 48 hours before subsiding.

NEUGENE antisense drugs are particularly suited to prevent this process because they can be delivered immediately following injury to the angioplasty site by a variety of means including catheter and stent elution, or by systemic delivery using AVI's microparticle delivery system, Resten-MP. Coronary artery bypass graft CABG surgery is performed about , times annually in the United States, making it one of the most commonly performed major operations. CABG surgery is advised for selected groups of patients with significant narrowings and blockages of the heart arteries coronary artery disease.

CABG surgery creates new routes around narrowed and blocked arteries, allowing sufficient blood flow to deliver oxygen and nutrients to the heart muscles. The primary therapeutic endpoint of the study is the subsequent reduction in luminal diameter late loss from the time of intervention to follow-up at six months, as measured by quantitative angiography and intravascular ultrasound.

Reduction in late loss is the standard indicator cardiologists use to gauge long-term stent efficacy. The University of Essen, in Germany, is the principal investigative center. Raimund Erbel, director of cardiology at the center, has appointed PD Dr. Stefan Sack as the principal investigator to coordinate the study, with the other German centers participating in the trial including the University of Heidelberg and the Coburg Clinical Center.

The world's largest privately held manufacturer of medical devices with international headquarters in Bloomington, Ind. Skip to main navigation. Sarepta Therapeutics is a U. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy DMD drug candidates.